Issue

Vol. 25 No. 3 (2013): Vol 25 Issue 3

Copyright (c) 2013 AJC

Creative Commons License

This work is licensed under a Creative Commons Attribution 4.0 International License.

Metoprolol Tartrate-An Ideal Drug Candidate for Transdermal Antihypertensive Therapy: It's Preliminary Preformulation Screening

https://doi.org/10.14233/ajchem.2013.13108
Mithun Bhowmick
Nandha College of Pharmacy and Research Institute, Erode-638 052, India
Sengodan Tamizharasi
Nandha College of Pharmacy and Research Institute, Erode-638 052, India
Nitin Dubey
College of Pharmacy, IPS Academy, Indore-452 012, India
Kundan Rewanand Gaidhane
Nandha College of Pharmacy and Research Institute, Erode-638 052, India
Thangavel Sivakumar
Nandha College of Pharmacy and Research Institute, Erode-638 052, India

Corresponding Author(s) : Mithun Bhowmick

mithun211@gmail.com

Asian Journal of Chemistry, Vol. 25 No. 3 (2013): Vol 25 Issue 3

Abstract

Metoprolol tartrate is the antihypertensive drugs that have been explored for its transdermal delivery potential in the present preliminary preformulation screening. Metoprolol tartrate is a selective adrenergic blocking agent, has become a widely used therapeutic agent for mild and moderate hypertension. Plasma elimination half-life (< 4 h), molecular weight (< 750) and poor bioavailability (40-60 %) due to extensive first pass metabolism, makes metoprolol tartrate a suitable candidate for transdermal drug delivery. However the transdermal route of administration cannot be employed for a large number of drugs therefore before going into the actual formulation of transdermal drug delivery system of metoprolol tartrate, other parameters has also been investigated in the present paper i.e., drug identification by advanced techniques like FTIR/ DSC, determination of lmax and plotting of calibration curve of the drug, physicochemical properties of the drug (solubility, melting point, partition coefficient log P), in vitro permeation study through porcine skin via determination of steady-state flux, permeability coefficient, diffusion coefficient, lag time and permeation enhancement study by permeation enhancers such as SLS, DMSO and oleic acid. The results suggested that metoprolol tartarate is the ideal drug for transdermal drug delivery system and SLS, DMSO and oleic acid induced a significant increase in drug permeation, with DMSO showing the highest enhancing effect at the lowest concentration (5 %) applied and hence may assist in the development of an effective transdermal formulation of metoprolol tartrate for use in humans.

Keywords

Metoprolol tartrate Hypertension Preformulation Solubility Melting point Partition coefficient Porcine skin Steady-state flux Permeability coefficient Diffusion coefficient Lag time
Bhowmick, M., Tamizharasi, S., Dubey, N., Rewanand Gaidhane, K., & Sivakumar, T. (2012). Metoprolol Tartrate-An Ideal Drug Candidate for Transdermal Antihypertensive Therapy: It’s Preliminary Preformulation Screening. Asian Journal of Chemistry, 25(3), 1501–1504. https://doi.org/10.14233/ajchem.2013.13108
Download Citation
Endnote/Zotero/Mendeley (RIS)
BibTeX
References
  1. Y.W. Chien, In eds.: J.R. Robinson and V.H.L. Lee, Transdermal Therapeutic System, Controlled Drug Delivery Fundamentals and Applications, New York, Marcel Dekker, edn. 2, pp. 524-552 (1987).
  2. J. Hadgraft and M.E. Lane, Int. J. Pharm., 305, 2 (2005).
  3. S. Jain and S.C. Joshi, Pharmacol. Online, 1, 379 (2007).
  4. M.H. Alderman, Am. J. Hypertens., 20, 347 (2007).
  5. V.G. Jamakandi, B. Ghosh and J. Khanam, Indian J. Pharm. Sci., 68, 556 (2006).
  6. R.P. Selvam, A.K. Singh and T. Sivakumar, Int. J. Pharm. Biomed. Res., 1, 1 (2010).
  7. K. Partiff, Martindale: The Complete Drug Reference, The Pharmaceutical Press, London, edn. 32, pp. 907-908 (1999).
  8. C.M. Anthony, O.M. David and W. Brian, Clark's Analysis of Drugs and Poisons, The Pharmaceutical Press, London, Vol. 2, edn. 3, pp. 1275-1276 (2004).
  9. R.L. James, In ed.: Klaus Florey, Metoprolol Tartrate, In; Analytical Profiles of Drug Substances, Academic Press, New York, Vol. 12, pp. 325-357 (1995).
  10. R.R. Katkam, S. Chakkapan and R. Shrivastava, Indian J. Pharm. Sci., 56, 121 (1994).
  11. M.K. Das, A. Bhattacharya and S.K. Ghosal, Indian J. Pharm. Sci., 68, 41 (2006).
  12. T. Murthy, R.P. Mallikarjuna and K. Murali, Pharmacol. Rev., 56, 145 (2004).
  13. I. Diez, H. Colom and R. Moreno, J. Pharm. Sci., 80, 932 (1991).
  14. Indian Pharmacopoeia, NISCAIR, Council Of Scientific & Industrial Research, New Delhi, Vol. 1, p. 244 (2007).
  15. I. James, Pharmaceutical Preformulation, Ellis Horwood Limited, Chiechesta, England, pp. 46-48 (1988).
  16. A. Jain, B. Ghosh and B. Desai, Eur. J. Pharm. Biopharm., 69, 958 (2008).
  17. M. Gouda, S. Shyale and P.R. Kumar, J. Chem. Pharm. Res., 2, 187 (2010).
  18. V. Kotwal, K. Bhise and R. Thube, AAPS Pharm. Sci. Technol., 4, E-1 (2008).
  19. K. Singh, Drug Develop. Ind. Pharm., 22, 471 (1996).
  20. R.O. Potts and R.H. Guy, Pharm. Res., 9, 663 (1992).
  21. J. Hadgraft, Eur. J. Pharm. Biopharm., 58, 291 (2004).
Read More
Author biographies is not available.
Download
PDF
Statistic
Read Counter : 0 Download : 0